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Abstract
Orofacial movement disorders (OMD) are a group of conditions that affect the motor aspect 
of the trigeminal, facial, and hypoglossal cranial nerves. These alterations are produced 
by pathologic disorders affecting the central nervous system, manifesting as isolated or 
combined hyperkinetic dysfunctional activities on the masticatory, facial mimic, or tongue 
musculatures. A comprehensive understanding of orofacial dystonias is essential to iden-
tify different variants of OMD that could be easily mislabeled or misdiagnosed. In this 
chapter, the authors focus on different aspects of the pathophysiology, epidemiology, 
clinical features, and management of orofacial dystonias and other movement disorders 
that are poorly recognized but not uncommon presentations of OMD, such as orofacial 
dyskinesias, drug-induced orofacial reactions, tardive orofacial syndromes, and bruxism.
Keywords: oromandibular dystonia, orofacial dystonias, orofacial dyskinesias, tardive 
dyskinesias, drug-induced extrapyramidal reactions, sleep bruxism/awake bruxism
1. Introduction
The first written medical description of OMD was made in 1910 in Dr. Meige’s paper entitled 
“Le convulsion de la Face, une forme clinique de convulsione faciale Bilateral et Mediane.” 
However, the clinical features outlined by Dr. Meige were not the first description of the 
phenomena, some pictorial representations dating from the sixteenth century were the first 
recorded description of OMD. Meige’s description summarized the clinical signs featured in 
orofacial dystonia, differentiating them from other movement disorders that affect the lower 
half of the face. He also emphasized relevant details such as the involvement of different 
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structures of the lower face, the description of specific precipitating factors, maneuvers that 
tended to milden and restrained the involuntary movement disorders, or their complete remis-
sion during sleep. Almost half a century later, OMD started to gain attention again [1].
Oromandibular dystonias (OMDy) are focal dystonias affecting the motor aspects of tri-
geminal, facial, and hypoglossal cranial nerves. Most OMDy are diagnostically challenging, 
mainly because they may have numerous presentations and severities, triggers may be hard 
to recognize, and orofacial movements may be quiescence during periods being often pri-
mary or idiopathic [2]. Consequently, OMDy may be commonly mistaken with temporoman-
dibular disorders, spontaneous condylar dislocation, hemimasticatory or hemifacial spasm, 
and psychogenic disorders [3–7]. In this chapter, the authors focus on different aspects of the 
pathophysiology, epidemiology, clinical features, and management of OMDy that may be 
useful to identify them from other movement disorders that are poorly recognized but not 
uncommon, such as orofacial dyskinesias, tardive orofacial syndromes, and bruxism.
2. Oromandibular dystonia
2.1. Definition and clinical presentation
Oromandibular dystonia is an infrequent form of focal dystonia, which affects the lower half 
of the face and mandible [8]. It manifests like sustained or intermittent, involuntary muscle 
contractions, which can cause repetitive movements of the lower facial, masticatory or tongue 
muscles or sustained abnormal postures in the lower face [9]. Dystonic oromandibular move-
ments may present as isolated or combined movements, affecting an isolated group of man-
dibular muscles (e.g., symmetric contraction of the elevators of the mandible, producing jaw 
closing dystonia) or various groups of muscles (asymmetric or alternated contraction of jaw 
depressors and elevators resulting in mandibular tremor or jaw deviating dystonia) [9].
Because clinical presentations are not uniform, focal OMDy can be characterized phenom-
enologically by the functional motor activity involved in the oromandibular movement. 
Consequently, OMDy can be subdivided into different subtypes: jaw-opening dystonia, jaw-
closing dystonia, jaw-deviating oromandibular dystonia, perioral dystonias, and/or lingual 
oromandibular dystonia [10]. When OMDy occurs together with blepharospasm, it is usually 
called cranial dystonia or Meige syndrome [11]. Toloza and Marti suggested that most cases of 
OMDy occur in combination with blepharospasm, only manifesting independently in 2–23% 
of the cases [12]. Isolated jaw-closing dystonia seems to be the more prevalent form of OMD 
and is less likely to be associated with other craniocervical dystonias. Approximately 32% of 
jaw OMDy are associated with facial grimacing, lip pursing, or other facial contortions [13]. 
Spontaneous remission is uncommon but may occur within the first 5 years [11]. Morning 
benefit (milder symptoms during morning) and overflown phenomenon (aberrant muscle 
activation during certain tasks) are also relatively common in OMDy patients [14].
The dystonic muscle contractions may interfere with several orofacial motor activities like 
mastication, swallowing, and verbal and non-verbal communication, explained probably by 
the uncoordinated and deviated muscle masticatory activity with antagonist cocontractions 
Dystonia - Different Prospects10
found in electromyographic studies [15]. Also, depending on the subtype of OMDy, patients 
may present trismus, dental wear, uncontrollable tooth clenching or grinding, frequent oral 
ulcers, forceful involuntary closures, jaw dislocation, dental restorations damage or frac-
tures, temporomandibular joint overload, facial contortions, lip sucking or smacking, lip 
pursing, chewing-like movements, mouth retraction, and platysma contractions [13, 16–18]. 
Generally, the masticatory spams disappear during sleep [19].
OMDy can be triggered by mandibular activities, such as talking, yawning, chewing, or swal-
lowing, often causing severe social impairment, reduced quality of life, and weight loss [20–22]. 
Also, patients frequently report exacerbating factors such as emotional stress and other daily 
activities like driving, reading, praying, looking upward/downward, or chewing [11]. Jaw 
and facial pain is also frequent and can often mislead the clinician, especially because OMDy 
are rare, may have remittance periods, and triggers are usually hard to identify [23]. Sensory 
trick (“geste antagonistique”) may ameliorate OMDy symptoms temporarily, being more 
effective in jaw-opening dystonia more than jaw-closing dystonia [24, 25].
2.2. Epidemiology
The prevalence of the dystonic oromandibular movements varies within the different reports. 
In the United States, the estimated prevalence has been reported from 0.52 to 30 cases per 
100,000 [26–28]. Other studies have reported a prevalence of 6.9 cases per 100,000 and an inci-
dence of 3.3 cases per million [26, 29]. Women seem to be more affected than men, in a female: 
male ratio of 3:1, typically with adult age onset near the sixth decade of life (more prevalent 
between 45 and 75 years) [9, 29]. A recent multicentric study featuring centers from the United 
States, Canada, Germany, Australia, England, France, and Italy reported that from all forms 
focal dystonia, OMDy had a prevalence of 8.7%, being one of the less prevalent subtypes of 
focal dystonia [30] (Table 1).
2.3. Etiology
The etiology of OMDy may be primary (idiopathic) or secondary. The primary form is the 
most common form of OMDy, not involving any central nervous system pathology, brain 
lesion, or tumor. Studies by Tan and Jankovic reported that most of OMDy were primary, 
accounting for 63% of the cases reported [31]. The pathophysiology of OMDy is currently 
Number of cases %
Primary 11 44
Neurodegenerative diseases (Parkinson’s disease, 
Huntington’s disease, other)
9 36
Secondary neuroleptic 3 12
Functional 2 8
Table 1. Prevalence and etiology OMD from Movement Disorders Tertiary Center, Centro de Trastornos de Movimientos 
(CETRAM), Chile, January 2014–October 2015.
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unknown, but several pathophysiological explanations have been pondered as probable 
causes, such as basal ganglia dysfunction, hyperexcitability of motor neurons interneurons 
related to signaling pathways, loss of inhibition, aberrant dopamine signaling, monoaminer-
gic dysfunction, abnormal plasticity, and abnormal sensory function [32–34].
The most common cause of secondary dystonia is tardive dystonia (drug-induced) reported 
in 22.8% of the cases. Other causes described are peripheral-induced OMDy in 9.3% of the 
cases, postanoxic states OMDy representing 2.5% of the cases, neurodegenerative disorders 
1.8%, and head injury-associated OMDy accounting for 0.9% of the cases [13].
Tardive OMDy produced by haloperidol, thioridazine, and metoclopramide accounts for the 
majority of the reports of drug-induced cases. Also, calcium channel blockers antivertiginous 
drugs such as flunarizine and cinnarizine have also been associated with OMDy [35].
Secondary OMDy can be caused by brainstem lesions, cerebrovascular disease, traumatic 
brain injury, and neurodegenerative disorders including multiple system atrophy, progres-
sive supranuclear palsy, Huntington’s disease, and neuroacanthocytosis. OMDy secondary 
to neurodegenerative disorders often present coexisting symptoms, such as chorea, seizures, 
amyotrophy, or subcortical dementia [19].
Peripheral trauma is a known to be causative or predisposing factors in several neurological 
disorders. Despite that most reports relating orofacial or dental trauma/procedures to OMDy 
are mostly anecdotal, the precise relation of peripheral trigeminal trauma and the onset of 
OMDy is still unclear [36].
Traumatic injuries, fractures, surgeries, and peripheral trigeminal nerve deafferentation or 
amputation have been associated with the onset of OMDy [37]. Also, numerous ambulatory 
dental procedures have been described as possible causative or predisposing factors of OMDy 
[38]. Ill-fitting dentures, endodontic treatments, gingivectomy, tooth extraction, apicectomy, 
prosthodontics, TMJ arthroscopy, and dental implants had been reported in dental and neu-
rological literature [8, 39–44].
Sankhla et al., in a review of 9083 patients, reported that of a total 197 patients diagnosed 
with OMDy, 27 cases had a history of facial trauma prior the onset of the dystonia [45]. 
Jankovic and Van der Linden noticed that 65% of the dystonia and tremors were associated 
with trauma-induced events [37]. Causation, however, is scarce as dental interventions are 
widespread while OMDy is very infrequent [29].
Eleven gene mutations have been identified as putative causes of dystonia. Of those, DYT6/
THAP1 gene variations have been involved in early-onset, progressive craniocervical dysto-
nia (OMDy, spasmodic dysphonia, and cervical dystonia) [46].
2.4. Treatment approaches
The treatment of OMDy is challenging and often requires multidisciplinary evaluation. Proper 
dental and oral evaluation is needed to assess orofacial and oropharyngeal function [29]. Triggers 
(especially relevant to sensory tricks) and the subtype of OMDy should be carefully identified. 
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Audiovisual recordings may be helpful in analyzing both. Adequate nutrition must be main-
tained when OMDy interferes with nutrition [29].
Physical therapy or speech therapy can be helpful sometimes. Peripheral afferent blocks tar-
geted to the muscles with 5–10 ml 0.5% lidocaine solutions seem to improve unless tempo-
rarily OMDy, suggesting that somatosensory input may be relevant in the pathogenesis of 
dystonia [47].
Sensory tricks (geste antagoniste) do not seem to provide adequate long-term relief and many 
times requires actions that interfere with normal functional activities [29]. Reports indicate 
that sensory tricks like pressing the teeth or lips with the fingers, placing objects in the mouth 
(cigarettes, gum, or object between the molars or chin), singing, or humming may be helpful 
in one-third of the patients [24, 25, 45]. Oral appliances have shown to be useful in some 
cases [24, 42], especially when they successfully mimic the patient’s sensory tricks. Singer and 
Papapetropoulus suggested that sensory tricks worked better for jaw-opening dystonia rather 
than in jaw closing dystonia [16].
A recent study by Yoshida et al. found that older patients with intraoral sensory tricks were 
more likely to respond to an oral appliance treatment compared to patients who do not have 
sensory tricks. Also, the authors reported that splint therapy was more effective in patients 
with jaw-closing dystonia who reported sensory tricks that involved mastication [14].
Deep brain stimulation targeting the externus globus pallidus has shown some continued 
efficacy, reporting interesting result in patients with Meige syndrome, but the evidence is still 
preliminary [48–50].
Pharmacological treatment of dystonia is mostly based on empirical experience rather than 
supported by rationale scientific evidence [51]. Oral medications are rarely beneficial in 
improving dystonic symptoms and may include anticholinergic drugs, baclofen, dopaminer-
gic drugs, and benzodiazepines [52]. Tetrabenazine reported benefits in the treatment of the 
symptoms in 26 to 60% of OMDy patients but is frequently associated with important side 
effects like parkinsonism and suicidal ideation [7, 53]. Zolpidem in doses ranging from 5 to 
20 mg has shown some promising results, but since these findings are only in a relatively small 
number of cases, prospective clinical trials are needed to determine its effectiveness [54, 55].
Chemodenervation with botulinum toxin (BT) is considered by most to be the first line of 
treatment. However, there are no high-level clinical trials to support this claim, and the evi-
dence is mainly based on small series of cases [56]. Hallett et al. in an evidence-based review 
concluded that abobotulinumtoxin A and onabotulinumtoxin A have level C recommenda-
tion according to American Academy of Neurology Classification for the Quality of Evidence 
(AANC) and level U for incobotulinumtoxin A and rimabotulinumtoxin B (inadequate data 
or treatment still unproven) [57]. As expected, a recent systematic review that intended to 
evaluate the effectiveness of BT in OMDy concluded that due to the variability of the out-
comes there is insufficient evidence to recommend or refute BT as a treatment option [58]. 
Nonetheless the scarce data, empirical experience over past 20 years has shown that BT is an 
effective and safe approach in the treatment of OMDy [59]. Because OMDy encompasses a 
broad range of musculature, it is among the most challenging forms of focal dystonias to treat 
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with BT [60]. The outcome of the injection depends critically on proper muscle identification, 
dose selection, and managing patient's expectations [29].
2.5. Subtypes of OMDy, muscle selection, and botulinum toxin application 
technique
2.5.1. Jaw-closing dystonia
The muscles responsible for jaw closing are the masseters, temporalis muscles, and medial 
pterygoid muscles. In jaw-closing dystonia, the masseter and temporalis are the primary tar-
geted muscles, mainly because BT application is percutaneously and relatively easy to perform.
2.5.1.1. Masseter muscle
The masseter muscle is one of the major muscles of the mastication, with a thick quadrilat-
eral muscle disposition. It is primarily involved in the elevation of the jaw and the deviation 
during its ipsilateral activity. The anterior two-thirds (superficial Masseter) originates from 
the lower border of the zygomatic arch and the lateral surface of the ascending mandibular 
ramus, projecting downward and posterior to the lateral aspect of the lower border of the 
ramus (near the second molar in its anterior border) and mandibular angle (posterior border). 
The last third has a more posterior origin in the zygomatic arch projecting in a vertical direc-
tion towards the central part of the ramus [61, 62] (Figure 1).
Figure 1. Masseter muscle anatomy.
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The alignment of masseter muscle fibers is mostly oriented to give a biomechanical advantage 
towards performing jaw closing and elevation, also having some importance in lateral devia-
tion and protrusion of the mandible. Hence it is of primary importance in the treatment of 
jaw-closing dystonia.
The application of botulinum toxin must be individualized for each patient. Usually, 2–3 
points of injection are recommended  since the masseter is a superficial muscle, clinically 
palpable the technique can be performed without EMG guidance. The muscle is usually 
approached by inserting the needle injection 1 cm anterior to the posterior border of the 
ramus and is easily palpable by making the patient clench. If EMG is used, the EMG dis-
charges will ensure that the needle is in the masseter and not in the parotid gland [19] 
(Figure 2).
2.5.1.2. Temporalis muscle
The temporalis muscle is also one of the major mandibular elevators, consisting of three 
separate muscular fascicles with different vectorial orientations, displaying a distinctive fun 
shape and occupying almost the entire temporal fossa (conformed by the parietal, sphenoid, 
temporal, and zygomatic bones) on the lateral aspect of the skull.
Figure 2. Masseter muscle recommended injection sites.
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It has three different fascicles (anterior, middle, and posterior) that merge into one sole 
muscle coursing inferiorly and medially to the zygomatic arch, where they converge in the 
temporalis tendon to insert in the coronoid process.
The three fascicles are aligned in a different disposition. The anterior fibers are oriented vertically, 
the middle fibers are disposed on a diagonal orientation, and the posterior fibers possess a  more 
horizontal disposition. The three fascicles functioning altogether are involved in mandibular ver-
tical closure. Anterior and the middle fibers are primarily involved in jaw-closing activities. The 
posterior fibers involved in jaw closure, but also are influential in promoting the settlement of the 
temporomandibular joint condylar disc complex into the glenoid fossa and helping retrusion of 
the mandible after it is protruded. Lastly, it is described that the ipsilateral three fascicles may be 
relevant in stabilizing the jaw during lateral excursive movements [61, 62] (Figure 3).
The injection technique should be performing at least one point per fascicle. Identification 
of the anterior portion of the temporalis muscle can be challenging in certain occasions. An 
easy way to rapidly identify this fascicle is to ask the patient to perform opening, closing, and 
clench movements repeatedly. This maneuver will contract the anterior temporalis fibers and 
will help identify the puncture points. The muscle is approached perpendicular to its plane 
and as highly possible in the temporal fossa. Because of this wide radiating pattern, it is best 
to give 3–4 injections into the muscle [19] (Figure 4).
Figure 3. Temporalis muscle anatomy.
Dystonia - Different Prospects16
2.5.1.3. Medial pterygoid muscle
The medial pterygoid muscle or internal pterygoid muscle is a deep quadrilateral muscle of 
mastication, primarily involved in the elevation of the mandible. It has two distinct points of 
origin: first, the “deep head” emerging from the medial surface of the lateral pterygoid plate 
of the sphenoid. The second point, the “superficial head” arises from the maxillary tuberosity 
and the pyramidal process of the palatine bone. Both heads orientate in a posterior and infe-
rior direction, inserting at the medial surface of the ramus and mandibular angle via a shared 
tendinous insertion [62] (Figure 5).
The function of the medial pterygoid muscle is primary jaw closure and is considered a func-
tional analog of the masseter muscle. During contralateral mandibular deviation, it acts in 
conjunction with the ipsilateral inferior head of the lateral pterygoid muscle producing con-
tralateral translatory movement of the mandible and ipsilateral translation of the mandibular 
condyle. The bilateral activity of these muscles in conjunction with the bilateral activity of the 
inferior head of the lateral pterygoids results in jaw protrusion [63].
As the lateral pterygoid muscle, the medial pterygoid botulinum toxin application can be 
performed using an intraoral or extraoral approach.
Figure 4. Temporalis muscle recommended injection sites.
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There are two different forms of performing the extraoral injection into the medial pterygoid 
muscle. From below, inserting the EMG electrode about 0.5–1 cm anterior to the angle of 
the mandible along the interior aspect of the mandible and angled perpendicularly to the 
ascending mandibular ramus, the adequate positioning of the electrode should be verified by 
asking the patient to clench. While performing this approach, the clinician should be careful 
in avoiding the facial artery [19] (Figure 6).
The other approach is more technically complex because the electrode must traverse deep 
through an extensive amount of tissues and network of vessels (the pterygoid venous plexus). 
This extraoral approach requires to position the patient in a supine position with the mouth 
open wide. The punction site should be selected in the window bounded by the lower border 
of the zygomatic arch, the mandibular notch, the mandibular condyle, and the coronoid pro-
cess. Then, the needle electrode is directed caudally towards the medial pterygoid muscle [64].
The intraoral technique is easier to perform, especially for those who are more familiar with 
intraoral injections. The technique must be executed by palping the muscle intraorally and 
inserting the needle electrode through the pharyngeal wall until the muscle is reached [64].
2.5.2. Jaw-opening dystonia
The muscles involved in jaw opening are the inferior lateral pterygoids and the submental 
complex (which includes the digastrics, mylohyoid, and geniohyoid muscles). The primary in 
promoting jaw opening is the inferior lateral pterygoid. The submental complex has a secondary 
role in promoting jaw opening, primarily assisting jaw opening at the beginning of the aperture.
Figure 5. Medial and lateral pterygoid muscle anatomy.
Dystonia - Different Prospects18
2.5.2.1. Lateral pterygoid muscle
The lateral pterygoid muscle is a nonpalpable masticatory muscle located in the lateral por-
tion of the infratemporal region, primarily involved in both jaw closure and opening. Lateral 
pterygoid muscle consists of two independent “heads” or “belies” (superior and inferior) 
that have two separate functional roles. The superior head has his origin in the greater wing 
of the sphenoid bone. The fibers of the superior head primarily insert in the articular fovea 
of the mandibular condylar head (accounting 60–70% of the times). A less frequent anatomic 
variant is the insertion at the temporomandibular joint disc and capsular complex (30–40% 
of the times). Functionally, the superior head of the lateral pterygoid muscle acts as an active 
stabilizer of the condyle during the closure [62].
The inferior head of the lateral pterygoid has less diverse anatomic variations, having its origin 
in the outer surface of the pterygoid plate and inserting in the lower part of the anterior fovea 
of the condyle and condylar neck. When acting bilaterally, the inferior head of the pterygoid 
muscle produces jaw protrusion and jaw opening when it acts in conjunction with the supra-
hyoid muscles. During these activities, the superior head of the pterygoid muscle is inhibited, 
giving this muscle a unique role in mandibular movement depending on which part of the 
muscle is activated. Conversely, when the inferior head of the muscle is activated unilaterally, a 
contralateral deviation of the jaw is produced [63]. Therefore, the inferior head of lateral ptery-
goid is one of the main targets in jaw-opening dystonia and jaw-deviating dystonia (Figure 5).
The access to the lateral pterygoid is complicated and can be performed intraorally or extra-
orally. Both approaches (intraoral or extraoral) require the use of electromyographic guidance 
to ensure intramuscular injection.
Figure 6. Medial pterygoid muscle extraoral botulinum toxin application technique.
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In the intraoral injection, the patient should be semi-reclined with his/her mouth slightly 
open and deviated to the contralaterally to the side of the procedure. The insertion of the 
needle electrode is above the second molar mucobuccal fold. The electrode is directed inward, 
upward, and backward sliding close to the tuberosity until hitting the pterygoid plate (to 
inject the inferior head) [65]. The direction of the injection should be oriented towards the 
middle point of a virtual line connecting the ipsilateral ear’s tragus and lobe [66]. A counter-
resistance contralateral mandibular deviation can be performed once the needle electrode is 
placed to ensure EMG discharge (Figure 7).
The extraoral technique needs a more profound anatomical knowledge of the infratemporal 
fossa. The patient should be in a supine position, with the jaw opened at least 20–30 mm 
wide or sufficiently to create a window bounded by the zygomatic arch (above) and the 
mandibular notch (below), coronoid process limiting the anterior border, and the mandibu-
lar condyle to posterior. To perform the extraoral technique, the clinician should palpate the 
bony margins with the index and middle fingers. Once located the tentative puncture the 
needle electrode should be placed anteriorly to the temporomandibular joint and directed 
upward, forward, and deep under the zygomatic arch towards the sphenoid bones (which 
forms the sealing within the muscles lies) [67]. Some descriptions suggest that the point of 
entry to the technique is 35 mm from the external auditory canal (anterior to the condylar 
neck of the mandible) and 10 mm from the inferior margin of the zygomatic arch. Then, the 
needle is angled upward about 15° and directed towards the roots of the lasts upper molars 
to reach the inferior head of the lateral pterygoid [19]. The needle must penetrate (at least 
Figure 7. Intraoral injection technique to the inferior head of the lateral pterygoid muscle.
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30–40 mm) through the masseter muscle and temporalis tendon before reaching the inferior 
lateral pterygoid head (Figure 8a and b).
2.5.2.2. Submental complex
The submental complex is primarily involved in jaw-opening oromandibular dystonia. This 
complex of muscles is constituted by three of muscles: the digastric muscle, the mylohyoid 
muscle, and geniohyoid muscle.
2.5.2.2.1. Digastric muscle
Similar to the lateral pterygoid muscle, the digastric muscle has two distinct components: 
the anterior belly and the posterior belly. The anterior belly has origin at the digastric fossa 
located in the submental area near the midline. Its fibers extend posteriorly and inferiorly. The 
posterior belly has its origin in the mastoid notch of the temporal bone and extends inferiorly 
and anteriorly to join with the anterior belly at the intermediate tendon attached to the hyoid 
bone. Both bellies participate in the mandible depression (opening). However, the anterior 
has more functional activity during jaw opening, while the posterior belly is also involved in 
elevating the hyoid bone during mastication and swallowing.
2.5.2.2.2. Mylohyoid muscle
The mylohyoid muscle is flat triangular muscle immediately situated superior to the anterior 
belly of the digastric muscle. It has his origin at the mandibular mylohyoid line, extending 
from the mandibular symphysis to the last inferior molar. The more medial fibers go infe-
rior-medially and posterior towards the midline, where they meet with their contralateral 
Figure 8. (a) Anatomical landmarks for extraoral injection technique to the inferior head of the lateral pterygoid muscle. 
(b) Extraoral puncture site for the inferior head of the lateral pterygoid muscle.
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counterpart via mylohyoid raphe (where both muscles intermesh). The posterior fibers insert 
in the anterior surface of the hyoid bone. The mylohyoid assists mandibular opening and 
draws forward the hyoid bone during swallowing, thereby it also tends to push the tongue 
upwards (tongue protrusion). Likewise, the capacity to move the lingual floor from side to 
side helps mastication.
2.5.2.2.3. Geniohyoid muscle
The geniohyoid muscle is part of the oral cavity floor, primarily involved in drawing the 
hyoid bone forward during swallowing and assisting the opening of the mandible. It is a 
narrow muscle located superior to the medial border of the mylohyoid muscle. It originates 
from the mandibular inferior genial spine, extending backward and slightly downwards until 
it inserts on the anterior surface of the body of the hyoid bone.
In most occasions, the submental complex is almost fused together, making it difficult to 
separate one from another. These muscles can be palpated with the patient on an open 
mouth position. The recommended technique is performed by inserting the needle injection 
about 1 cm from the inferior border of the mandible, slightly lateral from the midline in 
both sides where the anterior digastric should be located. The anterior digastrics are easy 
to localize and are usually the initial muscles injected. If the clinical results are not satisfac-
tory or the jaw-opening dystonia is severe, injections into the lateral pterygoids should be 
considered [19] (Figure 9a and b).
2.5.3. Jaw-deviating dystonia
The contralateral lateral pterygoid works in conjunction with the ipsilateral medial pterygoid 
to deviate the mouth to opposite side. The temporalis pulls the jaw to the same side. The 
injections follow the abovementioned techniques.
Figure 9. (a) Suprahyoid complex anatomy and injection sites. (b) Extraoral puncture site for the suprahyoid complex.
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2.5.4. Perioral dystonia
The orbicularis oris is an intricated facial expression muscle that acts as an oral sphincter, 
consisting of numerous muscle fibers, partly from the orbicularis and partly from other facial 
muscles, that encircle the mouth. The angle and more lateral part of the muscle is formed by 
the buccinator, levator anguli oris, and the depressor anguli oris originating at the median 
plane of the lips (deep surface of the skin) in the maxilla and mandible. The fiber follows the 
trajectory of the upper and lower lips, inserting in the mucous membrane of the median lips. 
The orbicularis oris protrudes and purses the lips, producing grimacing of the mouth. Perioral 
BT application has been found beneficial in cases that produce severe social disability [68].
2.5.5. Lingual dystonia
Lingual dystonia is a rare but recognized form of OMDy, since the early descriptions made 
by Meige [11], only being present in about 7.6% of the OMDy cases [13]. Some authors have 
suggested that more severe forms may indicate the presence of heredodegenerative disease 
or secondary OMDy [69, 70]. However, there are also reports of severe forms of idiopathic 
tongue dystonia [70]. The most frequent form of lingual dystonia involves protrusive tongue 
movements that can be repetitive or sustained. Action-induced lingual dystonia can be trig-
gered by regular physiologic activities such as chewing, swallowing, or speaking [11, 71–73]. 
Lingual dystonia can be substantially disabling and social embarrassing. Pronounced drool-
ing is frequent in these patients. Also, patients may experience severe difficulties in feeding 
or wearing dental dentures if the dystonic movements tend to push food or objects out of the 
mouth [74]. Severe forms, only reported in secondary forms, may obstruct the upper airways 
and may even require intubation and respiratory support. If lingual dystonia coexists with 
jaw-closing dystonia, tongue biting may cause severe lingual mutilation [69]. BT injection 
seems to be an effective treatment approach in dystonic tongue protruding cases [74].
Since that most lingual dystonia cases are involved with tongue protrusive movements, the 
BT application often targets the genioglossus muscle.
Anatomically, the tongue is divided into two distinct sets of muscles: the extrinsic tongue 
muscles insert into the tongue from outside origins and the intrinsic tongue muscles insert 
into the tongue from origins within it. The extrinsic muscles move the whole tongue in dif-
ferent directions, whereas the intrinsic muscles allow the tongue to change its shape (such as 
curling the tongue in a loop or flattening it).
The genioglossus (genio = “chin”) is an extrinsic tongue muscle that originates on the man-
dible and allows the tongue to move downward and forward. It is a fan-shaped muscle that 
occupies the majority of the volume tongue body. It originates from the superior genial spine 
to insert into the hyoid body (inferior fibers) and ventral surface of the tongue (superior fibers 
of the muscle were then mix with the intrinsic muscles of the tongue). When both genioglossus 
muscles act bilaterally, it promotes tongue protrusion and makes the lingual dorsum concave. 
Unilateral action produces deviation of the tongue to the contralateral side. BT application 
can be performed with a direct injection on the dorsal anterior surface of the tongue, starting 
at first 5–10 units per side to prevent dysphagia (Figure 10).
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2.6. Evaluation of treatment outcome
Response to BT application can be assessed by self-reported, observation, or a few available 
rating scales. The Movement Disorders Society Task Force on dystonia rating scales suggested 
that Oromandibular Dystonias Questionnaire (OMDQ-25) still needs further assessment to be 
validated and recommended [75]. However, the OMDQ-25 is clinimetrically valid, reliable, 
and sensitive to change in evaluating psychosocial and health-related change and improve-
ment in OMDy [22]. Generalized dystonia rating scales, such as Burke-Fahn-Marsden Scale 
and the Unified Dystonia Ranking Scale, include orofacial subcomponents that can be use-
ful in assessing the severity of the OMDy, guiding the treatment, and assessing the clinical 
response [29] (Table 2).
Figure 10. Genioglossus muscle injection sites.
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3. Oromandibular dyskinesia and drug-induced extrapyramidal 
reactions
Orofacial dyskinesias are described as involuntary rhythmic, repetitive, and stereotypic move-
ments of the face, lips, and tongue [77]. Clinical phenomenology varies in complexity and 
severity, ranging from almost being unnoticeable to complete social impairment (inability to 
eat, wear prosthetic dental devices, or perform social activities). As OMDy, oral dyskinesias 
can be spontaneous (primary) or secondary. Secondary dyskinesias are mostly part of drug-
induced reactions or tardive syndromes but can also be secondary by subcortical infarcts, 
peripherally induced (related to edentulism and ill-fitting dentures), or be concomitant with 
neuropsychiatric conditions, dementia, or mental retardation [17, 78].
Milder forms of oral dyskinesias, featuring patterned and predictable stereotypies, are more 
common in spontaneous dyskinesia, dementia, neuropsychiatric conditions, and peripherally 
induced orofacial dyskinesias [2, 17]. Tardive orofacial dyskinesias are often more complex 
and severe, commonly labeled “Oro-Bucco-lingual” dyskinesias or “classic tardive dyskine-
sias” when the movements disorders manifest isolated [79].
Doses and muscle selection cited from [19], [29] and [76].
✔commonly injected in BT application opatative.
Table 2. Oromandibular dystonia subtypes, muscle identification and BT application.
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3.1. Spontaneous orofacial dyskinesias
Spontaneous orofacial dyskinesia (SOD) is one of the less common forms of orofacial dyskine-
sias [17]. This subset is difficult to identify, mainly because of the inadvertent exposure to an 
offending drug is hard to discard. Hence, this term is usually coined when a detailed clinical 
description and characterization are lacking. SOD seems to be more prevalent in elderly, more 
commonly affecting females than men. Reports indicate that oral dyskinesias tend to fluctuate 
in time and their prevalence is highly variable [80].
Estimations on the prevalence rates vary from 1.5 to 38% among the population [81]. Reports 
on prevalence vary from 1.5 to 4% in healthy elderlies, 3.7% daycare centers elderlies, and 
18–31.7% in elderly living at retirement homes [82–85]. The age-related factors involved in the 
onset of SOD are unknown and need further research.
Chronic schizophrenia patients have been reported to present more frequently SOD [86]. 
Descriptions of this coexistence between SOD and chronic schizophrenia patients have been 
made since before the introduction of antipsychotics drugs [87]. A study by Owens et al. showed 
that dyskinetic orofacial movements were present in chronic schizophrenia institutionalized 
patients with and without a history of chronic exposure to antipsychotic drugs, leading the 
author to suggest that the dyskinetic movements were probably related to the schizophrenia. 
However, some differences were observed between the two groups, showing more severe orofa-
cial dyskinesias the group exposed to antipsychotic drugs [88]. The presence of SOD in chronic 
schizophrenia and other neurological disorders, such as autism, mental retardation, Alzheimer’s 
disease, and Rett syndrome seems to be non-specific and needs further clarification [78].
3.2. Peripheral-induced dyskinesia
Peripherally oral factors have been suspected to play an important role in inducing orofacial 
dyskinesia. Edentulism, ill-fitting dentures, oral pain, and low perceived oral health seem to 
be strongly associated with oral dyskinesias [89].
Koller in a study, which compared 75 consecutive edentulous subjects to age-matched con-
trols with teeth, found that 16% (12 individuals) of the edentulous subjects presented oral 
dyskinesia. Of them, nine presented mild oromandibular stereotypes and three subjects pre-
sented more marked dyskinesia, all of them displaying less complex dyskinesias compared to 
drug-induced dyskinesias [90].
A cross-sectional study in 1018 non-institutionalized patients found a 3.7% rate of prevalence 
of SOD. Interestingly, the subjects affected by oral dyskinesias reported more frequently 
edentulism with a high prevalence of ill-fitting dentures, oral pain, and poor buccal health 
perception. Furthermore, 52% of the edentulous subjects reported ill-fitting problems with 
their dentures in a higher proportion than the nondyskinetic controls and the tardive dys-
kinesia patients, leading the authors to suggest that in the absence of other putative factors, 
edentulism and orodental problems may trigger oral dyskinesia [89]. The nature of this asso-
ciation between orofacial dyskinesias and oral health factors requires further investigation 
and clarification and could be especially important to identify which dental factors may be 
amenable by good dental healthcare.
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3.3. Drug-induced orofacial reactions and tardive orofacial dyskinesias
Shortly after the introduction of conventional neuroleptics, Frank Ayd in 1961, published 
a list of medications associated with various movement disorders, which he named drug-
induced extrapyramidal reactions [91]. Since then, various reports associated with the use of 
medications and drugs were described and probably remain an important source of adult and 
pediatric movement disorders [92–95].
The terminology “Extrapyramidal Syndrome Reactions (ESR)” is commonly used in psychia-
try to refer drug-induced dystonia, akathisia, and parkinsonism [96]. However, phenomeno-
logically the term ERS lacks clarity, and clinically, the spectrum of persistent hyperkinetic and 
hypokinetic motor abnormalities is more precisely fitted into three distinct categories regarding 
their temporal profiles: acute and subacute drug-induced movement disorders and tardive 
syndromes. Acute drug-induced movement disorders often occurs within hours or days after 
the offending drug exposure; in subacute drug-induced movement disorders, the onset of the 
abnormal movements builds up slowly, after days or weeks of exposure [97]. Finally, tardive 
syndromes are due to the chronic exposure, almost never before than 3 months or 1 month in 
patients older than 60 years old, primarily after the exposure to dopamine receptor blocking 
agents (DRBA) [98].
3.3.1. Acute orofacial drug-induced movement disorders
Acute orofacial drug-induced movement disorders are primarily related to acute dystonic 
reactions, seen after the consumption of neuroleptics, emetics and gastrointestinal promo-
tility agents, antidepressants, amphetamines, antiepileptics, and recreational drugs, among 
many others [99–101].
Typically, acute dystonic orofacial reactions start after a few days the offending drug is intro-
duced, with 50% of the cases occurring during the first 24 hours and 90% of the cases within 
the first 5 days [99]. Motor symptoms are usually restricted to the head and neck, particularly 
as OMDy and complex cervical dystonias. Prevalence ranges from 2.3 to 60% and 2 to 3% in 
patients treated with typical DRBA and atypical DRBA, respectively [102].
Management consists in the suspension of the implicated drug, whenever is possible. 
Intramuscular or intravenous anticholinergic drugs are the most effective agents in treating 
acute dystonic reactions until the offending drug wears off. Benzodiazepines may be helpful 
but are not as effective as anticholinergics [99].
3.3.2. Tardive syndromes and tardive orofacial dyskinesias
The term “tardive syndromes” refer to a group of iatrogenic delayed onset of drug-induced per-
sistent movement disorders [103]. Two essential aspects must be present to configure a tardive 
syndromes diagnosis. The first aspect is that continuous exposure to the offending drug must 
be present, more frequently seen in prolonged treatments with DRBA. If there is no medical 
history of prolonged exposure, another diagnostic should be considered. The second essential 
aspect is that regardless of the duration of the exposure, the abnormal movements will persist, 
continue, and often worsen after the offending drug is withdrawn [96].
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In some patients, dyskinetic movements may appear immediately after the discontinuation, 
change, or reduction in dosage of neuroleptic medications, in which case the condition is 
called neuroleptic withdrawal-emergent dyskinesia. Because withdrawal emergent dyskine-
sia is usually time-limited, lasting less than 4–8 weeks, dyskinetic movements that persists 
beyond this window are considered as tardive dyskinesia [104].
Since the introduction of neuroleptics (DRBA), numerous reports emerged describing delayed 
orofacial involuntary stereotypies. Faurbye in 1964 initially coined the term “tardive dyskinesia” 
to describe late onset rhythmic, repetitive, persistent orofacial movements after long exposure to 
antipsychotic drugs [105, 106]. Other drugs distinct than DRBA have been related to tardive syn-
dromes such as anti-emetics, tricyclic antidepressants, calcium channel blockers, norepinephrine 
selective reuptake inhibitors, and serotonin selective reuptake inhibitors can cause abnormal 
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In literature, this term is often used to define various types of hyperkinetic tardive manifestations. 
However, because many patients may present a combination of tardive abnormal movements, it 
is more appropriate to use the term “tardive syndromes” to classify all the different tardive phe-
nomenologies including classic tardive dyskinesia, tardive stereotypy, tardive dystonia, tardive 
akathisia, tardive tremor, tardive parkinsonism, and tardive gait, among others [98].
Of the aforementioned tardive syndromes, the more prevalent presentations are classical 
tardive dyskinesia 30%, tardive akathisia 20%, and tardive dystonia 5–15% of the cases. Tics, 


























Cited from: [78, 98, 107].
Table 3. Medications with the potential to cause orofacial tardive dyskinesia and drug-induced reactions (listed 
alphabetically).
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A study by Orti-Pareja et al. described the frequencies of the different types of phenomenolo-
gies in a population of 100 patients diagnosed with tardive syndromes. The authors found 
that 72% of the patients presented oro-bucco-lingual dyskinesias, 30% tardive tremor, 22% 
tardive akathisia, and 16% tardive dystonia. In this study, 35% of the patients presented a 
combination of two or more tardive syndromes [108].
The presumed pathophysiology is thought to be related to chronic blockage of D2 and D3 
dopamine receptors. Typical antipsychotics are more tightly bind and for more time to 
dopamine receptors than “atypical” antipsychotics, being more prone to produce tardive 
dyskinesia [109]. Other prominent mechanisms may be the facilitation of dopaminergic 
neurotransmission, postsynaptic supersensitivity, maladaptive neuroplasticity, increased 
neurodegeneration (neuronal loss, gliosis in the basal ganglia), and genetic susceptibility 
[110–112].
3.3.3. Tardive orofacial dyskinesias
Classical tardive dyskinesias or “tardive orofacial dyskinesias” are characterized by hav-
ing an insidious onset of the symptoms, predominantly manifesting as relatively rhythmic, 
repetitive, and stereotypic movements of the face, mouth, tongue, and chewing movements 
(oro-bucco-lingual) [96].
Tardive dyskinesias tend to evolve into a full syndrome over days or weeks, persisting years 
or even decades after the offending drug is discontinued [107].
The clinical features often involve repetitive jaw movements, tongue protrusion, puffing of 
cheeks, lip smacking, lip puckering, or lip pursing affecting speech, swallowing, chewing, 
and occasionally producing tongue injuries. The onset of vertical, rhythmic perioral move-
ments of the jaw with frequencies of 2.5–5.5 Hz (rabbit syndrome) or jaw tremor have also 
been described in chronic exposure to neuroleptics [77]. The abnormal oro-buccal-lingual 
movements can also extend to other body parts, including the trunk or the extremities [98].
With typical antipsychotics, the estimated prevalence is between 20 and 50% [113]. The 
estimated incidence is about 5% in younger individuals but tends to increase in middle age 
individuals and elderlies, particularly in women, probably due to the cumulative exposure 
to DRBA [107].
Tardive orofacial dyskinesia is potentially reversible in a subset of patients. However, remis-
sion rates after the discontinuation of the offending drug is relatively low, about 13% of the 
patients experienced complete resolution after 3 years and only 2% without having to include 
other pharmacological agents [114].
Treatment recommendations focus on patient selection (paramount for preventing tardive dys-
kinesias), use alternative medications whenever is possible, and making emphasis on avoiding 
long DRBA treatments. Slowly tapering of the offending drug is recommended mostly because 
sudden withdrawn can trigger withdrawn emergent dyskinesia [98, 107]. Evidence supports the 
idea that as sooner the causative drug is retrieved, the more likely is that tardive dyskinesia will 
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resolve [111]. Patients requiring antipsychotic drugs switching to atypical neuroleptics may still 
have risk of developing tardive dyskinesia [115]. About 60% of the patients will benefit with the 
reintroduction of the drug, but only for a low period of time [24].
Dopamine-depleting agents like tetrabenazine can be used in severe cases with moderate to 
good results. Other agents such as amantadine, clonazepam (only for short periods of time), 
vitamins, and antioxidants may help lessen tardive orofacial dyskinesia, but the evidence 
available is still inconclusive. Botulinum toxin injections have shown efficacy in reducing tar-
dive dyskinesia in several clinical reports and small studies [98, 107].
4. Sleep and awake bruxism
4.1. Definition
Bruxism comes from the Greek term brukhein “to gnash the teeth” [116]. Research on sleep 
medicine, the pathophysiology of sleep and awake bruxism, and related comorbidities has 
changed old dental mechanistic beliefs based on dental occlusion to a more medical concept, 
hardly influenced by peripheral factors [117–119].
Bruxism is a trigeminal motor activity characterized by a repetitive and episodic muscle con-
tractions producing grinding or clenching of the teeth, or bracing or thrusting of the mandible. 
By consensus, it can be categorized into two different circadian manifestations, occurring dur-
ing sleep (Sleep Bruxism) or wakefulness (Awake Bruxism), being tooth grinding dominant 
during sleep and clenching activities more prevalent during wakefulness [120–122]. Evidence 
suggests that sleep bruxism and awake bruxism are probably not part of the same nosologic 
entity, each having some substantial similarities but probably having different etiologies and 
pathophysiology [123]. Sleep bruxism is considered a sleep-related movement disorder, and it 
is hardly controllable during sleep [124]; meanwhile, awake bruxism is an unaware stereotypic 
mandibular activity during wakefulness, when cognizant can be voluntarily controlled and 
terminated [116].
4.2. Diagnosis
During sleep, bruxism can be registered by quantifying the episodes of rhythmic activity of the 
masticatory muscles (also known as rhythmic masticatory muscle activity or RMMA) [125]. 
The RMMA corresponds to a rise in the electromyographic activity of the electrodes placed 
in the masticatory muscles and the chin, and it is produced by muscle contractions with a 
frequency of 1 Hz, helping distinguish it from other oromandibular movements or disorders 
during sleep (e.g., mandibular myoclonus, nocturnal vocalization, snoring, or swallowing) 
[126]. RMMA can take three forms of bursting patterns: (1) isolated muscle contraction lasting 
>2 s called “tonic”; (2) more than three bursts lasting 0.25–2.0 each, called “phasic”; and (3) 
the mixture between tonic and phasic bursts. It is important to note that RMMA may present 
with little or no tooth grinding at all [127].
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A panel of international experts defined a diagnostic criterion, grading sleep bruxism into 
three diagnostic levels: The first criteria consists only in the anamnestic report, the second 
criteria adds to the anamnetic report a clinical assessment, and the third and definitive 
diagnostic level is based on a polysomnographic study [120, 124]. From the anamnestic 
standpoint, the presence of recent self-reported tooth grinding sounds during sleep is nec-
essary, noted also or confirmed by a parent or a sleep partner. The second diagnostic level 
includes the anamnestic report plus clinical signs of abnormal tooth wear, the presence of 
jaw muscle fatigue or pain, temporal headache, or jaw locking upon wakefulness. Not better 
explained by other sleep disorders, medical or neurologic disease, medication use, or drug 
abuse [120].
Regardless that these two first diagnostic levels are widely accepted, evidence shows that 
report-based diagnosis in bruxism are subjective, possibly bias, lacks of acceptable specific-
ity and sensitivity and needs further validation [125]. Then, some considerations should 
be taken into account before making an anamnesis-based or clinical diagnosis. First and 
foremost, studies have shown almost 50% discordance between PSG recording and self-
reports, showing that self-report studies tend to overestimate bruxism [128, 129]. Also, it 
should be considered that tooth grinding tends to fluctuate with time and decline with age 
[130, 131]. Recent data shows that the assessment of sleep bruxism using subjective methods 
alone tends to overestimate the prevalence in 12.5% compared to PSG recordings [129, 132]. 
Moreover, a recent study aiming to assess the sensibility, specificity, and positive and nega-
tive predictive value among the different clinical diagnostics compared to PSG recordings 
found that the more sensitive clinical criteria corresponded to jaw fatigue upon awakening 
followed by a temporal headache. The most specific diagnostic criteria were jaw locking and 
muscle pain [133].
Awake bruxism is usually more difficult to diagnose, mostly because diagnosis relies on self-
awareness of individual [134]. However, there is increasing evidence suggesting that once a 
person is made aware of their awake bruxism habits, he or she is more likely to give accurate 
feedback [135, 136].
4.3. Epidemiology
The prevalence of sleep bruxism is estimated mainly based on reports, being it highest dur-
ing childhood approximately 14–20%, consolidating around 8–12% during adolescence and 
adulthood, and decreasing over 50 years to 3–5%. Several studies have found that when SB is 
present during childhood, it may persist into adulthood. However, as previously mentioned, 
most subjects show fluctuations and alternating periods of SB during the lifespan. Awake 
bruxism has been reported to have an estimated prevalence of 22.1–31% among the adult 
population [130, 131, 137].
4.4. Sleep and awake bruxism pathophysiology
Current understanding of the etiology and pathophysiology of SB is not based on a single 
factor explanatory model [138]. Instead, much of the pathological mechanisms are unknown 
or not well understand and are subject to interindividual variability [139].
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Sleep bruxism starts with a cascade of physiological events that are temporally related to 
the onset of the RMMA episode [139]. Four to eight minutes before the onset, a cardiac sym-
pathetic activity dominance can be observed [140, 141]. The cardiac autonomic activity is 
followed by an increase of electroencephalographic activity dominated by rapid frequency 
brain activity, i.e. arousal, in 50–80% of the episodes [142, 143]. Then, a rise in heart rate, 
fluctuations in respiratory breaths and oxygen saturation, a rise in the systolic and diastolic 
pressure, and an increase of suprahyoid muscles tone usually precede the onset of the RMMA 
[144–146]. This sequence of event is not always constant to all RMMA but highlights that 
sleep bruxism involves a complex interaction between the sympathetic system, cortical arous-
ability, and respiratory functions. Posterior to the RMMA onset and the tooth grinding, most 
of the episodes are followed by swallowing (~60%) [147]. Sporadic RMMA is not infrequent 
in general population. However, individuals presenting sleep bruxism have more RMMA 
with more intense bursting patterns, manifesting primarily in pre-REM sleep during transi-
tions between NREM1 and NREM2 stages [126, 138]. Sleep bruxism-induced muscle activity 
during REM sleep is less concurrent accounting for less than 10% of the RMMA episodes 
during sleep [125]. Individuals with sleep bruxism do not present alterations in their sleep 
architecture unless they present a comorbidities [129] (Figure 11).
4.5. Sleep bruxism etiology
Multifactorial etiology of SB includes individual factors such as personality traits, environ-
mental factors, genetics, circadian and ultradian rhythms, coping skills (anxiety/stress), neu-
rotransmitters (more probably serotoninergic-related pathways), anatomic characteristics, 
sleep arousability, airway patency, and sleep disturbances among other factors.
Stress, anxiety, and maladaptive coping skills have been related to sleep and awake bruxism. 
Individuals with sleep bruxism usually are more stressed and exhibit more goal-oriented per-
sonalities and higher anxiety levels [148–151]. In children and adolescents, psychological fac-
tors have been found to be a putative risk for bruxism [152]. Personality traits and behaviors 
Figure 11. Sleep bruxism episode in a polysomnography study. Courtesy of Somno Clinic, Chile. www.somno.cl.
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like bullying, aggressiveness, neuroticism, increased sense of responsibility, tense personality 
traits, and antisocial conduct are associated with sleep bruxism [153–155].
Genetic predisposition is also postulated as an important etiologic factor, accounting for 
48–52% of sleep bruxism phenotypic variance [156]. Heritability strongly correlates with sleep 
bruxism having a relative risk of 4.6 [157–159]. Single nucleotide polymorphisms of serotonin-
ergic and dopaminergic neurotransmission have emerged as potential candidates showing 
strong association with an increased risk of sleep bruxism [160, 161]. These associations have 
not been found in awake bruxism which further support the idea that sleep and awake brux-
ism are two different nosologic manifestations [161].
Caffeine intake in high quantity is linked with an increased risk of sleep bruxisms in 1.5 times 
[162] through mechanisms currently unknown [163]. Heavy drinking and frequent alcohol 
intake during the day have also been associated with sleep bruxism. It is thought that frag-
mentation of sleep architecture and accumulation of neurotransmitters related to dopaminer-
gic and serotoninergic pathways may be associated with the exacerbation of sleep bruxism 
[162, 163]. Similarly, tobacco consumption increases the risk of having sleep bruxism two 
times [162]. As well, several drugs and medications have shown activity in exacerbating sleep 
bruxism such as levodopa, selective serotonin reuptake inhibitors, tricyclic antidepressants, 
amphetamines, and MMDA, among others [127, 164, 165].
Airway patency studies have shown a positive association between sleep bruxism and sleep 
breathing disorders [166, 167]. In fact, about 50% of adults and children with obstructive 
sleep apnea present concomitant sleep bruxism [168–170]. Furthermore, self-reports studies 
in sleep apnea patients increase the risk of having bruxism, probably mediated by the occur-
rence of sleep arousals during respiratory events [171]. It has been hypothesized that the 
relation of sleep bruxism concomitant or posterior to hypopnea or apnea episodes may have 
a role in reinstating airway permeability during the events, suggesting a causative link [172]. 
However, there is not enough evidence to support this claim [173].
Nocturnal gastroesophageal reflux is another factor associated with sleep bruxism. Higher 
frequencies of SB episodes were associated with having more time of esophageal pH below 
5.0 [174]. Miyawaki et al. showed a concomitance of RMMA events and gastroesophageal 
reflux episodes, more particularly when episodes had a pH lower than 3.0–4.0 [174]. Also 
finding the sleep position during sleep was influential in reducing RMMA and episodes of 
gastroesophageal reflux alike [175]. Moreover, clinical trials measuring the effect of proton 
pump inhibitors (PPI) in patients with comorbidity of sleep bruxism and gastroesophageal 
reflux have shown that the consumption of PPI reduces RMMA episodes of sand grinding 
noises significantly [176].
4.6. Management
In the absence of treatable comorbidities, treatment of sleep bruxism is not plausible. Instead, 
management should be focused on preventing tooth destruction and grinding and alleviating 
temporomandibular pain or concomitant headaches [125, 177]. Oral appliances tend to reduce 
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sleep bruxism episodes only in short-term, returning to the baseline activity within 7–10 days 
[178]. A recent systematic review showed the effectiveness of almost every type of oral appli-
ances, providing a higher decrease of sleep bruxism episodes those that produce a certain 
extent of mandibular advancement (mandibular advancement devices) [178, 179].
In the presence of concomitant sleep breathing disorders, the first step should be taken towards 
managing sleep breathing disorders depending on the severity. In these cases, a mandibular 
advancement device or the use of CPAP should be preferred over upper maxillary appliances, 
mostly because evidence suggests that they may produce aggravation of hypopnea and apnea 
episodes [180, 181].
Pharmacotherapy for management sleep bruxism is mainly based on the use of off-label med-
ication; only a few medications have shown some degree of effectiveness in reducing sleep 
bruxism. Clonazepam and clonidine have proven to reduce bruxism with respect to placebo 
[179]. A single-blinded, randomized controlled trial suggested that the use of gabapentin may 
be effective for the management of sleep bruxism especially in those patients with poor qual-
ity of sleep, but these preliminary results still need further corroboration with better designed 
clinical trials and more number of participants [182].
Botulinum toxin effects are in line with the expected pharmacologic effects; they are superior 
to placebo [183]. However, studies have shown that the use of botulinum toxin reduces the 
intensity of the RMMA bursts but not the frequency, which further confirms the central gen-
esis of sleep bruxism episodes [184].
Regarding awake bruxism, EMG-based biofeedback programs seem to reduce tonic episodes 
of awake and sleep bruxism alike [185, 186].
A pilot study using mindfulness-based stress reduction programs has also shown efficacy in 
the management of awake bruxism (Unpublished data from Skarmeta et al.).
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